Stock Quote

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications to date. Injectable collagenase (collagenase clostridium histolyticum or CCH) is marketed as XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture and Peyronie's disease by BioSpecifics' partner, Endo International plc (Endo). XIAFLEX® is also commercialized in Japan, Europe, Canada and Australia for Dupuytren’s contracture and for Peyronie's disease in Europe and Australia.

Endo is partnered with Paladin Labs, Sobi, Actelion and Asahi Kasei for Dupuytren's contracture and/or Peyronie's disease outside of the U.S.

Corporate Presentation
Recent and Upcoming Events
Wednesday, September 27, 2017
1:05pm EDT
Tuesday, September 12, 2017
11:40am EDT
Tuesday, June 6, 2017 - Friday, June 9, 2017
Wednesday, April 5, 2017
8:00am EDT
Tuesday, November 15, 2016
8:00am EST
Tuesday, August 9, 2016
4:30pm - 4:59pm EDT
Thursday, June 9, 2016
8:00am EDT
Wednesday, April 13, 2016
10:40am EDT
Tuesday, March 15, 2016
12:30pm PDT